Takeda and Seagen to Present Results of Adcetris (brentuximab vedotin) for the Treatment of Advanced Hodgkin Lymphoma at ASCO 2022
Shots:
- The P-III (ECHELON-1) trial evaluates Adcetris + AVD vs ABVD in 1,334 patients with prior untreated stage III or IV classical Hodgkin lymphoma
- The results showed an improvement in OS at a median follow up of 73mos., 41% reduction in risk of death with an estimated OS rate (93.9% vs 89.4%) & PFS rate (82.3% vs 74.5%) @6yr., treatment-emergent peripheral neuropathy (86% vs 87%), completely resolving (72% vs 79%), and improving (14% vs 8%) by the last follow-up. The safety profile was consistent with prior studies with no new safety signals
- Seagen has US & Canadian commercialization rights & Takeda will lead the development costs & got the rights to commercialize Adcetris globally. The companies share the equal cost for Adcetris on a 50:50 basis (Ex-Japan)
Ref: Seagen | Image: Seagen
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
